BOTHELL, Wash.--(BUSINESS WIRE)-- <\/p>\n
Seattle Genetics, Inc. (NASDAQ:SGEN - News) today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. A summary of the companys poster presentations is below and full abstracts can be accessed on the ASCO website at http:\/\/www.abstract.asco.org<\/a>. <\/p>\n ADCETRIS <\/p>\n Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study <\/p>\n CD30 expression in non-lymphomatous malignancies <\/p>\n Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study <\/p>\n ASG-5ME <\/p>\n Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC) <\/p>\n About ADCETRIS <\/p>\n ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. <\/p>\n<\/p>\n See the rest here:<\/p>\n Seattle Genetics to Present ADCETRIS\u00ae and ASG-5ME Data at ASCO Annual Meeting<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. Continue reading